502 related articles for article (PubMed ID: 19804686)
1. Rituximab for the treatment of rheumatoid arthritis.
Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
3. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
6. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
7. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
[TBL] [Abstract][Full Text] [Related]
14. Telbivudine for the treatment of chronic hepatitis B infection.
Hartwell D; Jones J; Harris P; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for the treatment of severe persistent allergic asthma.
Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
